Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectrum Pharmaceuticals has announced the formation of a Canadian affiliate, Spectrum Pharma Canada, headquartered in the province of Quebec, Canada.
Subscribe to our email newsletter
Rajesh Shrotriya, chairman, president, and CEO of Spectrum, said: “The establishment of Spectrum Pharma Canada is another important milestone as we build a global pharmaceutical organization.
“The Canadian research infrastructure, highly qualified talent pool, and economic incentives provided by the individual provinces, especially the province of Quebec, were all factors in the establishment of this affiliate.”
As announced in February 2008, the therapeutic product directorate of Health Canada approved clinical trials to be conducted in Canada by issuing a no objection letter to Spectrum’s clinical trial application for EOquin. Patients are being enrolled at approximately 30 clinical centers in Canada, including the province of Quebec.
The EOquin registration plan calls for two double blind, placebo-controlled, randomized Phase III clinical studies, each with 562 evaluable patients with Ta G1 or G2 low risk non-muscle invasive bladder cancer.